Breaking Finance News

Zacks Investment Research downgraded NeoGenomics, Inc. (NASDAQ:NEO) to Hold in a report released today.

Zacks Investment Research has downgraded NeoGenomics, Inc. (NASDAQ:NEO) to Hold in a report released on 9/28/2016.

Previously on 09/08/2016, Raymond James Financial Inc. reported about NeoGenomics, Inc. (NASDAQ:NEO) raised the target price from $0.00 to $10.00. At the time, this indicated a possible upside of 0.23%.

Yesterday NeoGenomics, Inc. (NASDAQ:NEO) traded 0.25% higher at $8.18. The company’s 50-day moving average is $8.10 and its 200-day moving average is $8.04. The last stock close price is up 1.70% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 140,337 shares of the stock were exchanged, down from an average trading volume of 326,794

See Chart Below

NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. has a 52 week low of $5.49 and a 52 week high of $9.54 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $9.63 with 4 firms rating the stock a strong buy, 2 firms rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.